Randomized, Multicenter, Phase II Study of CO-101 Versus Gemcitabine in Patients With Metastatic Pancreatic Ductal Adenocarcinoma: Including a Prospective Evaluation of the Role of hENT1 in Gemcitabine or CO-101 Sensitivity.

Research output: Contribution to journalArticle

Abstract

Gemcitabine requires transporter proteins to cross cell membranes. Low expression of human equilibrative nucleoside transporter-1 (hENT1) may result in gemcitabine resistance in pancreatic ductal adenocarcinoma (PDAC). CO-101, a lipid-drug conjugate of gemcitabine, was rationally designed to enter cells independently of hENT1. We conducted a randomized controlled trial to determine whether CO-101 improved survival versus gemcitabine in patients with metastatic PDAC (mPDAC) with low hENT1. The study also tested the hypothesis that gemcitabine is more active in patients with mPDAC tumors with high versus low hENT1 expression.

Details

Authors
  • Elizabeth Poplin
  • Harpreet Wasan
  • Lindsey Rolfe
  • Mitch Raponi
  • Tone Ikdahl
  • Ihor Bondarenko
  • Irina Davidenko
  • Volodymyr Bondar
  • August Garin
  • Stefan Boeck
  • Steffen Ormanns
  • Volker Heinemann
  • Claudio Bassi
  • T R Jeffrey Evans
  • Hejin Hahn
  • Vince Picozzi
  • Adam Dicker
  • Elaina Mann
  • Cynthia Voong
  • Paramjit Kaur
  • Jeff Isaacson
  • Andrew Allen
Organisations
Research areas and keywords

Subject classification (UKÄ) – MANDATORY

  • Cancer and Oncology
Original languageEnglish
Pages (from-to)4453-4461
JournalJournal of Clinical Oncology
Volume31
Issue number35
Publication statusPublished - 2013
Publication categoryResearch
Peer-reviewedYes